This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Neophore Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Martin Drysdale: Innovator in Cancer Treatment
Introduction
Martin Drysdale is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on targeting specific proteins involved in the DNA Mismatch Repair process, which is crucial for maintaining genomic stability.
Latest Patents
Martin Drysdale holds a patent for "Inhibitors of MLH1 and/or PMS2 for cancer treatment." This invention relates to compounds of Formula (I) that specifically target the MLH1 and/or PMS2 proteins. These proteins play a vital role in the DNA Mismatch Repair (MMR) process, and the compounds developed by Drysdale aim to enhance cancer treatment efficacy.
Career Highlights
Throughout his career, Martin has been associated with Neophore Limited, a company dedicated to advancing cancer therapies. His work has been instrumental in developing innovative solutions that address critical challenges in cancer treatment.
Collaborations
Martin Drysdale has collaborated with esteemed colleagues such as Paul Winship and David Clark. Their combined expertise has contributed to the advancement of research in the field of cancer treatment.
Conclusion
Martin Drysdale's contributions to cancer treatment through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in medical research and therapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile